Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
Meta Wants Users to Pay for AI. A New Subscription Is Launching
US Open: 10-Year Treasury Yield Breaks Above 5% as Wall Street Comes Under Pressure Ahead of Fed Decision
Morning Wrap: Brent at $107, AI sell-off (15.09.2026)
Michael Burry’s portfolio: Revolution or rebalance?